Eocene Ltd.
EOCN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.3% and free cash flow fell 67.7%, each against the same quarter a year earlier.
Follow EOCN
Eocene Ltd. (EOCN) EV/Sales
As of 16 October 2026, Eocene Ltd. (EOCN) trades at a EV/Sales of −3.0×. Over the past ten years it has ranged from −8.6× (June 2022) to 224× (June 2018); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2018 | 19.5× | (78.52%) |
| FY2017 | 90.9× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2018 | 19.5× | (77.66%) |
| Sep 2018 | 87.4× | 4.31% |
| Jun 2018 | 83.8× | 59.36% |
| Mar 2018 | 52.6× | (42.14%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EOCN Eocene Ltd. | −3.0× |
| APVO Aptevo Therapeutics Inc. compare | −0.3× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 2.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 18.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)